-
1
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
-
(2010)
Int J Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
2
-
-
33244463813
-
Complex networks orchestrate epithelial-mesenchymal transitions
-
Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
-
(2006)
Nat Rev Mol Cell Biol
, vol.7
, pp. 131-142
-
-
Thiery, J.P.1
Sleeman, J.P.2
-
3
-
-
0043172396
-
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
-
Grünert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657-665, 2003.
-
(2003)
Nat Rev Mol Cell Biol
, vol.4
, pp. 657-665
-
-
Grünert, S.1
Jechlinger, M.2
Beug, H.3
-
4
-
-
3142708765
-
Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver
-
Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S and Nishiguchi S: Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292: 358-361, 2004.
-
(2004)
JAMA
, vol.292
, pp. 358-361
-
-
Habu, D.1
Shiomi, S.2
Tamori, A.3
Takeda, T.4
Tanaka, T.5
Kubo, S.6
Nishiguchi, S.7
-
5
-
-
0029148360
-
The growth inhibitory effects of vitamins K and their actions on gene expression
-
Wang Z, Wang M, Finn F and Carr BI: The growth inhibitory effects of vitamins K and their actions on gene expression. Hepa to logy 22: 876-882, 1995.
-
(1995)
Hepa to Logy
, vol.22
, pp. 876-882
-
-
Wang, Z.1
Wang, M.2
Finn, F.3
Carr, B.I.4
-
6
-
-
34247537075
-
Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation
-
Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, Pestell RG and Yamamoto K: Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res 13: 2236-2245, 2007.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2236-2245
-
-
Ozaki, I.1
Zhang, H.2
Mizuta, T.3
Ide, Y.4
Eguchi, Y.5
Yasutake, T.6
Pestell, R.G.7
Yamamoto, K.8
-
7
-
-
41049091166
-
Vitamin K2 suppresses malignancy of HuH7 hepatoma cells via inhibition of connexin 43
-
Kaneda M, Zhang D, Bhattacharjee R, Nakahama K, Arii S and Morita I: Vitamin K2 suppresses malignancy of HuH7 hepatoma cells via inhibition of connexin 43. Cancer Lett 263: 53-60, 2008.
-
(2008)
Cancer Lett
, vol.263
, pp. 53-60
-
-
Kaneda, M.1
Zhang, D.2
Bhattacharjee, R.3
Nakahama, K.4
Arii, S.5
Morita, I.6
-
8
-
-
70449579247
-
Cytoskeletal changes during epithelial-to-fibro blastoid conversion as a crucial mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma
-
Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y and Saka moto A: Cytoskeletal changes during epithelial-to-fibro blastoid conversion as a crucial mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 35: 1005-1014, 2009.
-
(2009)
Int J Oncol
, vol.35
, pp. 1005-1014
-
-
Murata, K.1
Suzuki, H.2
Okano, H.3
Oyamada, T.4
Yasuda, Y.5
Sakamoto, A.6
-
9
-
-
51049098909
-
Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors
-
Dal Lago L, D'Hondt V and Awada A: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 13: 845-858, 2008.
-
(2008)
Oncologist
, vol.13
, pp. 845-858
-
-
Dal Lago, L.1
D'Hondt, V.2
Awada, A.3
-
10
-
-
81555231534
-
Early decrease in α-fetoprotein, but not des-γ-carboxy prothro mbin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma
-
Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, Tamaki S, Kato T, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M and Izumi N: Early decrease in α-fetoprotein, but not des-γ-carboxy prothro mbin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 81: 251-258, 2011.
-
(2011)
Oncology
, vol.81
, pp. 251-258
-
-
Kuzuya, T.1
Asahina, Y.2
Tsuchiya, K.3
Tanaka, K.4
Suzuki, Y.5
Hoshioka, T.6
Tamaki, S.7
Kato, T.8
Yasui, Y.9
Hosokawa, T.10
Ueda, K.11
Nakanishi, H.12
Itakura, J.13
Takahashi, Y.14
Kurosaki, M.15
Izumi, N.16
-
11
-
-
80051745537
-
Des-γ-carboxyprothrombin
-
may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
-
Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H and Sakurai T: Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 29: 321-325, 2011.
-
(2011)
Dig Dis
, vol.29
, pp. 321-325
-
-
Ueshima, K.1
Kudo, M.2
Takita, M.3
Nagai, T.4
Tatsumi, C.5
Ueda, T.6
Kitai, S.7
Ishikawa, E.8
Yada, N.9
Inoue, T.10
Hagiwara, S.11
Minami, Y.12
Chung, H.13
Sakurai, T.14
-
12
-
-
74549217434
-
Hypoxia-induced des-γ-carboxy prothrombin production in hepatocellular carcinoma
-
Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y and Sakamoto A: Hypoxia-induced des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 36: 161-170, 2010.
-
(2010)
Int J Oncol
, vol.36
, pp. 161-170
-
-
Murata, K.1
Suzuki, H.2
Okano, H.3
Oyamada, T.4
Yasuda, Y.5
Sakamoto, A.6
-
13
-
-
79960744370
-
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma
-
Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuji K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Kokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M and Omata M: Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 54 : 532-540, 2011.
-
(2011)
Hepatology
, vol.54
, pp. 532-540
-
-
Yoshida, H.1
Shiratori, Y.2
Kudo, M.3
Shiina, S.4
Mizuta, T.5
Kojiro, M.6
Yamamoto, K.7
Koike, Y.8
Saito, K.9
Koyanagi, N.10
Kawabe, T.11
Kawazoe, S.12
Kobashi, H.13
Kasugai, H.14
Osaki, Y.15
Araki, Y.16
Izumi, N.17
Oka, H.18
Tsuji, K.19
Toyota, J.20
Seki, T.21
Osawa, T.22
Masaki, N.23
Ichinose, M.24
Seike, M.25
Ishikawa, A.26
Ueno, Y.27
Tagawa, K.28
Kuromatsu, R.29
Sakisaka, S.30
Ikeda, H.31
Kuroda, H.32
Kokuryu, H.33
Yamashita, T.34
Sakaida, I.35
Katamoto, T.36
Kikuchi, K.37
Nomoto, M.38
Omata, M.39
more..
-
14
-
-
84874746017
-
Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma
-
Zhong JH, Mo XS, Xiang BD, Yuan WP, Jiang JF, Xie GS and Li LQ: Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS One 8: e58082, 2013.
-
(2013)
PLoS One
, vol.8
, pp. e58082
-
-
Zhong, J.H.1
Mo, X.S.2
Xiang, B.D.3
Yuan, W.P.4
Jiang, J.F.5
Xie, G.S.6
Li, L.Q.7
-
15
-
-
47949116252
-
SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
De Oliveira, A.C.7
Santoro, A.8
Raoul, J.L.9
Forner, A.10
Schwartz, M.11
Porta, C.12
Zeuzem, S.13
Bolondi, L.14
Greten, T.F.15
Galle, P.R.16
Seitz, J.F.17
Borbath, I.18
Häussinger, D.19
Giannaris, T.20
Shan, M.21
Moscovici, M.22
Voliotis, D.23
Bruix, J.24
more..
-
16
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
Tsao, C.J.4
Qin, S.5
Kim, J.S.6
Luo, R.7
Feng, J.8
Ye, S.9
Yang, T.S.10
Xu, J.11
Sun, Y.12
Liang, H.13
Liu, J.14
Wang, J.15
Tak, W.Y.16
Pan, H.17
Burock, K.18
Zou, J.19
Voliotis, D.20
Guan, Z.21
more..
-
17
-
-
0038049137
-
Tumour-cell invasion and migration: Diversity and escape mechanisms
-
Friedl P and Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362-374, 2003.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 362-374
-
-
Friedl, P.1
Wolf, K.2
-
18
-
-
0347052797
-
Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis
-
Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H and Mikulits W: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 566: 9-20, 2004.
-
(2004)
Mutat Res
, vol.566
, pp. 9-20
-
-
Gotzmann, J.1
Mikula, M.2
Eger, A.3
Schulte-Hermann, R.4
Foisner, R.5
Beug, H.6
Mikulits, W.7
-
19
-
-
48549084059
-
Hepatocyte-specific SMAD7 expression attenuates TGF-β-mediated fibrogenesis and protects against liver damage
-
Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K, Weng H and Mertens PR: Hepatocyte-specific SMAD7 expression attenuates TGF-β-mediated fibrogenesis and protects against liver damage. Gastroenterology 135: 642-659, 2008.
-
(2008)
Gastroenterology
, vol.135
, pp. 642-659
-
-
Dooley, S.1
Hamzavi, J.2
Ciuclan, L.3
Godoy, P.4
Ilkavets, I.5
Ehnert, S.6
Ueberham, E.7
Gebhardt, R.8
Kanzler, S.9
Geier, A.10
Breitkopf, K.11
Weng, H.12
Mertens, P.R.13
-
20
-
-
0036108620
-
Cadherin and catenin alterations in human cancer
-
Hajra KM and Fearon ER: Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34: 255-268, 2002.
-
(2002)
Genes Chromosomes Cancer
, vol.34
, pp. 255-268
-
-
Hajra, K.M.1
Fearon, E.R.2
-
21
-
-
34248148453
-
N-Cadherin signaling potentiates mammary tumor meta stasis via enhanced extracellular signal-regulated kinase activation
-
Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K and Hazan RB: N-Cadherin signaling potentiates mammary tumor meta stasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 67: 3106-3116, 2007.
-
(2007)
Cancer Res
, vol.67
, pp. 3106-3116
-
-
Hulit, J.1
Suyama, K.2
Chung, S.3
Keren, R.4
Agiostratidou, G.5
Shan, W.6
Dong, X.7
Williams, T.M.8
Lisanti, M.P.9
Knudsen, K.10
Hazan, R.B.11
-
22
-
-
0642336851
-
E-Cadherin expression in primary carcinomas of the breast and its distant metastases
-
Kowalski PJ, Rubin MA and Kleer CG: E-Cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5: R217-222, 2003.
-
(2003)
Breast Cancer Res
, vol.5
, pp. R217-R222
-
-
Kowalski, P.J.1
Rubin, M.A.2
Kleer, C.G.3
-
23
-
-
16844379257
-
Cadherin switching: Essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition
-
Maeda M, Johnson KR and Wheelock MJ: Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 118: 873-887, 2005.
-
(2005)
J Cell Sci
, vol.118
, pp. 873-887
-
-
Maeda, M.1
Johnson, K.R.2
Wheelock, M.J.3
-
24
-
-
0021073669
-
Cell-cell interaction and polarity of epithelial cells: Specific perturbation using a monoclonal antibody
-
Imhof BA, Vollmers HP, Goodman SL and Birchmeier W: Cell-cell interaction and polarity of epithelial cells: specific perturbation using a monoclonal antibody. Cell 35: 667-675, 1983.
-
(1983)
Cell
, vol.35
, pp. 667-675
-
-
Imhof, B.A.1
Vollmers, H.P.2
Goodman, S.L.3
Birchmeier, W.4
-
25
-
-
77956635530
-
Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion
-
Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC, Stiles B and Rountree CB: Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 52: 945-953, 2010.
-
(2010)
Hepatology
, vol.52
, pp. 945-953
-
-
Ding, W.1
You, H.2
Dang, H.3
LeBlanc, F.4
Galicia, V.5
Lu, S.C.6
Stiles, B.7
Rountree, C.B.8
-
26
-
-
77956769763
-
Hepatocyte growth factor-stimulated cell scattering requires ERK and CDC42-dependent tight junction disassembly
-
Togawa A, Sfakianos J, Ishibe S, Suzuki S, Fujigaki Y, Kitagawa M, Mellman I and Cantley LG: Hepatocyte growth factor-stimulated cell scattering requires ERK and CDC42-dependent tight junction disassembly. Biochem Biophys Res Commun 400: 271-277, 2010.
-
(2010)
Biochem Biophys Res Commun
, vol.400
, pp. 271-277
-
-
Togawa, A.1
Sfakianos, J.2
Ishibe, S.3
Suzuki, S.4
Fujigaki, Y.5
Kitagawa, M.6
Mellman, I.7
Cantley, L.G.8
-
27
-
-
78751523982
-
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial-mesenchymal transition in hepato - Cellular carcinoma
-
Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M and Nishio K: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial-mesenchymal transition in hepato - cellular carcinoma. Mol Cancer Ther 10: 169-177, 2011.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 169-177
-
-
Nagai, T.1
Arao, T.2
Furuta, K.3
Sakai, K.4
Kudo, K.5
Kaneda, H.6
Tamura, D.7
Aomatsu, K.8
Kimura, H.9
Fujita, Y.10
Matsumoto, K.11
Saijo, N.12
Kudo, M.13
Nishio, K.14
-
28
-
-
80052033164
-
c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
-
You H, Ding W, Dang H, Jiang Y and Rountree CB: c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54: 879-889, 2011.
-
(2011)
Hepatology
, vol.54
, pp. 879-889
-
-
You, H.1
Ding, W.2
Dang, H.3
Jiang, Y.4
Rountree, C.B.5
-
29
-
-
61949226823
-
Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
-
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD and Fan J: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49: 491-503, 2009.
-
(2009)
Hepatology
, vol.49
, pp. 491-503
-
-
Ke, A.W.1
Shi, G.M.2
Zhou, J.3
Wu, F.Z.4
Ding, Z.B.5
Hu, M.Y.6
Xu, Y.7
Song, Z.J.8
Wang, Z.J.9
Wu, J.C.10
Bai, D.S.11
Li, J.C.12
Liu, K.D.13
Fan, J.14
-
30
-
-
52449095361
-
The RSK family of kinases: Emerging roles in cellular signalling
-
Anjum R and Blenis J: The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758, 2008.
-
(2008)
Nat Rev Mol Cell Biol
, vol.9
, pp. 747-758
-
-
Anjum, R.1
Blenis, J.2
-
31
-
-
79952686342
-
ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex
-
Mendoza MC, Er EE, Zhang W, Ballif BA, Elliott HL, Danuser G and Blenis J: ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell 41: 661-671, 2011.
-
(2011)
Mol Cell
, vol.41
, pp. 661-671
-
-
Mendoza, M.C.1
Er, E.E.2
Zhang, W.3
Ballif, B.A.4
Elliott, H.L.5
Danuser, G.6
Blenis, J.7
-
32
-
-
0344845003
-
Epithelial-mesenchymal transitions in development and pathologies
-
Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746, 2003.
-
(2003)
Curr Opin Cell Biol
, vol.15
, pp. 740-746
-
-
Thiery, J.P.1
-
33
-
-
34547209343
-
Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
-
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
-
(2007)
Biochim Biophys Acta
, vol.1773
, pp. 1263-1284
-
-
McCubrey, J.A.1
Steelman, L.S.2
Chappell, W.H.3
Abrams, S.L.4
Wong, E.W.5
Chang, F.6
Lehmann, B.7
Terrian, D.M.8
Milella, M.9
Tafuri, A.10
Stivala, F.11
Libra, M.12
Basecke, J.13
Evangelisti, C.14
Martelli, A.M.15
Franklin, R.A.16
-
34
-
-
77955249585
-
Sora fenib for recurrent hepatocellular carcinoma after liver transplantation
-
Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK: Sora fenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 40 : 768-773, 2010.
-
(2010)
Jpn J Clin Oncol
, vol.40
, pp. 768-773
-
-
Yoon, D.H.1
Ryoo, B.Y.2
Ryu, M.H.3
Lee, S.G.4
Hwang, S.5
Suh, D.J.6
Lee, H.C.7
Kim, T.W.8
Ahn, C.S.9
Kim, K.H.10
Moon, D.B.11
Kang, Y.K.12
|